XT
iShares Exponential Technologies ETF
$83.35
iShares Exponential Technologies ETF (XT) Price & Chart
XT ETF Chart & Stats
$83.35
At close: 4:00 PM EST- Day’s Range
- $82.92 - $83.84
- 52-Week Range
- $65.47 - $85.85
- Previous Close
- $82.32
- Volume
- 37.15K
- Average Volume (3M)
- 64.06K
- AUM
- 3.93B
- NAV
- 83.44
- Expense Ratio
- 0.46%
- Holdings Count
- 195
- Beta
- 1.12
- Inception Date
- Mar 19, 2015
- Last Dividend Ex-Date
- Jun 15, 2026
- Dividend Yield
- (6.83%)
- Shares Outstanding
- 47,700,000
- Standard Deviation
- N/A
ETF Overview
iShares Exponential Technologies ETF
The iShares Exponential Technologies ETF (XT) is an innovative investment vehicle that captures the dynamism of the Information Technology sector through a broad-based approach. This ETF is meticulously designed for investors seeking exposure to cutting-edge technological advancements that are reshaping industries across the globe. By focusing on exponential technologies, XT taps into a diversified array of sectors including robotics, nanotechnology, bioinformatics, and artificial intelligence, among others. XT stands out in its niche by not merely concentrating on traditional tech giants but by embracing a wide array of transformative companies that are pioneering future-defining technologies. This strategic positioning allows investors to capitalize on the growth potential of emerging trends and innovations that drive significant economic and societal shifts. With a carefully curated portfolio, the ETF aims to provide robust growth opportunities and long-term value appreciation for investors eager to participate in the next wave of technological evolution. Whether you're a seasoned investor or new to the tech investment landscape, the iShares Exponential Technologies ETF offers a compelling blend of innovation, diversification, and growth potential.
- Asset Class
- Equity
- Region
- Global
- Issuer
- iShares
- Index Tracked
- Morningstar Exponential Technologies Index
- Ticker Symbol
- XT
XT ETF News
AbbVie Crohn’s Disease Study Update Offers Limited Near-Term Stock Impact
Abbvie ($ABBV) announced an update on their ongoing clinical study. Study Overview: AbbVie’s official study, “A Post-marketing Non-interventional Study for Upadacitinib in Patients With Moderately to Severely Active Crohn’s Disease
25m agoABBV
XT ETF FAQ
What was XT’s price range in the past 12 months?
XT’s lowest price in the past 12 months was $65.47 and its highest was $85.85.
What is the AUM of XT?
As of Nov 11, 2026, the AUM of XT is $3.93B.
Is XT overvalued?
Based on Wall Street analyst price targets for XT’s holdings, XT’s price is currently undervalued.
Does XT pay dividends?
Yes. XT pays dividends semi-annually. Its most recent dividend was $0.36 per share, and its annual dividend yield is 6.83%. See more information on XT dividends here.
How many shares outstanding does XT have?
XT has 47,700,000 shares outstanding.
